Matches 1 - 50 out of 87 1 2 >


Match Document Document Title
US20160136258 PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS  
The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition...
US20100239608 PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS  
The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The...
US20090104230 COMPOSITIONS AND METHODS OF USING CAPSID PROTEIN FROM FLAVIVIRUSES AND PESTIVIRUSES  
This invention provides methods of inducing cell death with Flavivirus or Pestivirus capsid protein, such as West Nile virus (WNV) capsid protein, and functional fragments thereof. The invention...
US20080311156 VACCINES  
The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an...
US20070298053 Cattle reproductive disease vaccines  
The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1...
US20140141070 LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES  
Nucleic acid immunisation is achieved by delivering a RNA encapsulated within a liposome comprising a cationic lipid, wherein the liposome and the RNA have a N:P ratio of between 1:1 and 20:1.
US20120107355 METHOD OF RAPIDLY PRODUCING IMPROVED VACCINES FOR ANIMALS  
A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an...
US20110293723 SYNTHETIC NANOCARRIER COMBINATION VACCINES  
Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are...
US20060159704 Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and other infectious agents  
The present invention relates to a vaccine against infections caused by flavivirus. More particularly to the use of the YF vaccine virus (17D) to express at the level of its envelope, protein...
US20050002968 Flavivirus vaccines  
The invention provides attenuated flavivirus vaccines and methods of making and using these vaccines.
US20100330121 RECOMBINANT ALPHAVIRUS-BASED VECTORS WITH REDUCED INHIBITION OF CELLULAR MACRO-MOLECULAR SYNTHESIS  
Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered...
US20080026071 Microparticles for delivery of heterologous nucleic acids  
Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy...
US20070231350 West Nile vaccine  
The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as...
US20160120972 INACTIVATED DENGUE VIRUS VACCINE WITH ALUMINIUM-FREE ADJUVANT  
The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.
US20130028934 Stabilizer and Vaccine Composition Comprising One or More Live Attenuated Flaviviruses  
The present invention relates to stabilizers for compositions, including immunogenic compositions, such as vaccine compositions, comprising one or more live attenuated flaviviruses, to bulk...
US20100270202 Method of Immunization Against the 4 Dengue Serotypes  
The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising (a) a first series of administrations (i) of a dose of a vaccinal dengue virus...
US20070212376 Method of treating and preventing infectious diseases  
The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found...
US20090191240 Flavivirus Vaccines  
The invention provides flavivirus vaccines and methods of making and using these vaccines.
US20120244182 USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION  
The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance...
US20100047280 FLAVIVIRUS NS1 SUBUNIT VACCINE  
The present invention relates to NS1 proteins or parts thereof of Flaviviruses, in particular of Dengue viruses useful for vaccination against said Flavivirus and against one or more other...
US20090263470 Vaccine Compositions Comprising Virosomes and a Saponin Adjuvant  
This invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing from said virus, and a saponin adjuvant. In particular the invention provides...
US20140302091 METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES  
Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live,...
US20130115244 Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant  
The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide...
US20130095136 Tetravalent Dengue Vaccines  
The invention provides tetravalent Dengue vaccines, and methods of using these vaccines to prevent or to treat Dengue infection.
US20160102099 ANTI-VIRAL COMPOUNDS  
Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells,...
US20140112953 INACTIVATED DENGUE VIRUS VACCINE  
The present invention provides formulations of an immunogenic composition containing a purified inactivated Dengue virus, and method for producing them.
US20130323280 METHODS FOR PREPARING VESICLES AND FORMULATIONS PRODUCED THEREFROM  
The present disclosure provides methods for preparing vesicles. In one aspect, the methods involve providing a molten mixture of vesicle-forming lipids and adding the molten mixture of...
US20120114693 NUCLEIC ACID MUCOSAL IMMUNIZATION  
Mucosal delivery of antigens using, for example, a replication-defective gene delivery vehicle, particularly replication-defective alphavirus vectors and particles, is described. Also described...
US20100239612 Method of Immunization Against the 4 Serotypes of Dengue Fever  
The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising: (a) the administration of a monovalent vaccine comprising a vaccinal...
US20090246223 Inactivated Chimeric Vaccines and Related Methods of Use  
Embodiments of the present invention generally provide an inactivated chimeric virus vaccine and/or immunogenic composition for the treatment or prevention of viral infection. Further, various...
US20060204523 Flavivirus vaccine delivery system  
A flaviviral expression vector, construct and system are provided that each comprise a flaviviral replicon that faciliates intracellular self-replication leading to high-level expression of RNA...
US20110045024 RNA VIRUS VACCINES AND METHODS  
The invention is a vaccine, and method of vaccination, against RNA viruses, including RNA viruses in the family Flaviviridae, which includes for example West Nile Virus, Yellow fever virus, Dengue...
US20160122312 ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF  
Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of viral infection, including RNA viral infection, as well as compounds, pharmaceutical compositions, and...
US20150265695 VACCINE COMPOSITIONS FOR PREVENTION AGAINST DENGUE VIRUS INFECTION  
The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.
US20140314739 Vaccine adjuvant composition comprising inulin particles  
The present invention provides a composition comprising or consisting of inulin particles for use in the reduction or inhibition of inflammation, and/or for treating or preventing inflammatory...
US20140227321 ANTI-VIRAL COMPOUNDS  
Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells,...
US20110223197 Mucosal and Systemic Immunization with Alphavirus Replicon Particles  
Mucosal and systemic administration of compositions comprising alphavirus replicon particles to induce immune responses in a subject is described.
US20100221285 Method of Immunization Against the 4 Dengue Serotypes  
The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a...
US20090041852 DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION  
This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said...
US20120021001 MARKED BOVINE VIRAL DIARRHEA VIRUS VACCINES  
The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of...
US20100233209 Chikungunya virus infectious clones and uses therefor  
The present invention developed and characterized in vitro and in vivo three full-length cDNA clones based on the alphavirus chikungunya, two sets of infectious clones based on CHIKV and replicons...
US20080171002 Products For Receptor Mediated Activation And Maturation Of Monocyte-Derived Dendritic Cells By A Phosphorylated Glucomannane Polysaccharide  
Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve...
US20120003277 NANOEMULSION VACCINES  
The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more...
US20070185025 Filoviral immunosuppressive peptides and uses thereof  
The invention provides a region of strong secondary structure conservation between the C-terminus domain of the envelope glycoprotein of filoviruses and an immunosuppressive domain found in...
US20130078261 ENVELOPED VIRUS VACCINE AND METHOD FOR PRODUCTION  
The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified,...
US20070298093 Synergistic Liposomal Adjuvants  
The present invention relates to liposome, mixtures or liposomes and liposomal compositions comprising at least two different adjuvants and a therapeutic agent, their production and use for the...
US20090012494 INTRADERMAL DELIVERY OF BIOLOGICAL AGENTS  
The present invention relates to methods for intradermally delivering one or more biologically active agents such as vaccines and therapeutic agents into the dermis layer of the skin of a subject...
US20060198854 Vector platforms derived from the alphavirus vaccines  
Nucleic acid molecules and vector platforms derived from human virus vaccines, for example the alphavirus vaccines, including the TC-83 human vaccine, are disclosed. These vector platforms can...
US20150150960 PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE DENGUE DISEASE  
The invention provides uses, methods and compositions for eliciting, stimulating, inducing, promoting, increasing, or enhancing an anti-Dengue virus T cell response in a subject.
US20140050763 MODIFIED VIRAL PARTICLES WITH IMMUNOGENIC PROPERTIES AND REDUCED LIPID CONTENT USEFUL FOR TREATING AND PREVENTING INFECTIOUS DISEASES  
The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are...

Matches 1 - 50 out of 87 1 2 >